IQV Earnings Prediction
The chart below shows how IQV performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IQV sees a -0.06% change in stock price 10 days leading up to the earnings, and a +1.88% change 10 days following the report. On the earnings day itself, the stock moves by +1.33%. This data can give you a slight idea of what to expect for the next quarter's release.
IQV Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.90B
4.28%
2.15%
Gross Margin
28.23%
4.13%
1.88%
Operating Margin
14.84%
8.48%
3.27%
Net Margin
7.32%
-9.74%
-23.11%
EPS
1.55
-4.91%
-21.32%
No Data Available
IQV Earnings Analysis
IQVIA Holdings Inc. Corporation (IQV.N) Earnings Conference Call
Positive
Revenue Growth Analysis: 1. Strong Revenue Growth: IQVIA reported a revenue of $3.896 billion for Q3 2024, reflecting a 6.5% growth year-over-year when excluding COVID-related work.
Backlog Milestone Achieved: 2. Record Backlog: The company's backlog reached a new record of $31.1 billion, representing an 8% increase compared to the previous year.
Adjusted EPS Growth: 3. Increased Adjusted EPS: Adjusted diluted earnings per share rose to $2.84, marking a 14.1% increase year-over-year.
Strong Demand Indicator: 4. Healthy Book-to-Bill Ratio: The trailing 12-month book-to-bill ratio stood at 1.22x, indicating strong demand and future revenue potential.
Strong Free Cash Flow Growth: 5. Robust Free Cash Flow: IQVIA generated a free cash flow of $571 million in Q3, demonstrating a 31% year-over-year increase and a 109% cash conversion of adjusted net income.
Negative
Trial Cancellations Impact Revenue: 1. Significant Trial Cancellations: A major cancellation due to drug futility impacted quarterly net new business by approximately $350 million, affecting overall bookings and revenue projections.
Contract Sales Revenue Decline: 2. Decline in Contract Sales Revenue: Contract Sales and Medical Solutions revenue decreased by 1.6% reported and 1.1% at constant currency, indicating a downturn in this segment.
COVID Revenue Decline: 3. Reduced COVID-Related Revenue: COVID-related revenues fell sharply to approximately $20 million, down from about $100 million in the same quarter last year, reflecting a significant decline in this revenue stream.
Net Debt Concerns: 4. Increased Net Debt: As of September 30, net debt stood at $11.940 billion, resulting in a net leverage ratio of 3.27x trailing 12-month adjusted EBITDA, indicating a concerning level of debt relative to earnings.
Revised Revenue Expectations: 5. Lowered Guidance Due to Delays: The company updated its full-year guidance to reflect delays in two mega trials, now expected to resume in 2025, which negatively impacts short-term revenue expectations.
IQV FAQs
How does IQV typically perform around its earnings report dates?
Is IQVIA Holdings Inc. (IQV) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IQV Earning Call Sentiment
IQVIA Holdings Inc. (IQV) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
IQV.N
1.31%Positive
The earnings call reveals mixed signals: strong financial metrics with record backlog and revenue growth, but offset by competitive pressures, regulatory issues, and significant project cancellations. The optimistic guidance is tempered by trial delays and unclear management responses in the Q&A, which could concern investors. The share repurchase program is a positive, but the lack of clear guidance for 2025 adds uncertainty. Overall, these factors suggest a neutral stock price movement over the next two weeks.